Patents by Inventor Georg Winter
Georg Winter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132485Abstract: The present invention relates to compounds with the ability to stimulate/induce ubiquitination of a target protein/target proteins. The compounds of the present invention may stimulate/induce ubiquitination of a target protein/target proteins; i.e. via degradation of a target protein/target proteins by the cullin-RING ubiquitin ligase (CRL). Such target protein/target proteins may be proteins involved in diseases, like cancer, metabolic disorder, infectious disease and/or neurological disorder. The invention also relates to the compounds and composition for use as medicaments as well as pharmaceutical compositions comprising these compounds. Particularly, the compounds of the present invention may degrade proteins associated with cancer, metabolic disorder, infectious disease and/or neurological disorder.Type: ApplicationFiled: October 15, 2021Publication date: April 25, 2024Inventors: Georg WINTER, Cristina MAYOR RUIZ, Stefan KUBICEK, Alastair David Graham DONALD, Grasilda ZENKEVICIUTE
-
Publication number: 20240018951Abstract: A thruster system for use in a spacecraft combines chemical and electric or electrothermal propulsion. To that end a thruster may comprise a cavity including at least one inlet to receive a first fluid and a second fluid configured to chemically react with the first fluid within the cavity to generate a reaction product. Alternatively, the cavity may be configured to receive a monopropellant configured to chemically decompose within the cavity. The thruster system further comprises an energy source coupled to the cavity and configured to heat or ionize material within the cavity by emitting electromagnetic radiation. Still further, the thruster system comprises a nozzle provided at one end of the cavity and configured to direct heated material out of the cavity to generate thrust.Type: ApplicationFiled: July 12, 2022Publication date: January 18, 2024Inventors: David Robert Buckley Biggs, Michael Werner Georg Winter, Joseph Mark Oorebeek, Robert Erik Schwarz, Charles Jonathan Chase
-
Publication number: 20230241226Abstract: The present invention relates to compounds of formula compounds of formulae (I) by which transmembrane proteins such as SLC transporters can be unlocked to chemically-induced degradation, whereby a multitude of diseases can be addressed for the first time. Particularly, the present invention relates to compounds with the ability to induce degradation of SLC transporters via the ubiquitin-proteasome pathway. The invention also relates to the compounds and composition for use as medicaments as well as pharmaceutical compositions comprising these compounds, particularly for use as degraders of SLC transporters which are, e.g., associated with cancer and for use in the treatment of various diseases such as cancer. Furthermore, the present invention relates to a method for treating a disease or condition, such as cancer, comprising administering the compound of the present invention.Type: ApplicationFiled: October 16, 2020Publication date: August 3, 2023Applicant: CeMM - Forschungszentrum für Molekulare Medizin GmbHInventors: Ariel BENSIMON, Georg WINTER, Gulio SUPERTI-FURGA
-
Publication number: 20230131952Abstract: The present application provides bifunctional compounds of Formula (X): or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for protein kinases. The present application also relates to methods for the targeted degradation of one or more protein kinases through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to one or more protein kinases which can be utilized in the treatment of disorders modulated by protein kinases.Type: ApplicationFiled: December 15, 2022Publication date: April 27, 2023Applicant: Dana-Farber Cancer Institute, Inc.Inventors: James BRADNER, Dennis BUCKLEY, Mette Ishoey ROSENBAUM, Georg WINTER
-
Publication number: 20230124700Abstract: The present invention relates to compounds with the ability to stimulate/induce ubiquitination of a target protein/target proteins. The compounds of the present invention may stimulate/induce ubiquitination of a target protein/target proteins; i.e. via degradation of a target protein/target proteins by the cullin-RING ubiquitin ligase (CRL). Such target protein/target proteins may be proteins involved in diseases, like cancer, metabolic disorder, infectious disease and/or neurological disorder. The invention further relates to a method for identifying/obtaining and/or testing a compound able to induce ubiquitination of a target protein/target proteins. The invention also relates to the compounds and composition for use as medicaments as well as pharmaceutical compositions comprising these compounds. Particularly, the compounds of the present invention may degrade proteins associated with cancer, metabolic disorder, infectious disease and/or neurological disorder.Type: ApplicationFiled: October 16, 2020Publication date: April 20, 2023Applicant: CeMM - Forschungszentrum für Molekulare Medizin GmbHInventors: Georg WINTER, Cristina MAYOR RUIZ, Stefan KUBICEK
-
Patent number: 11583586Abstract: The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.Type: GrantFiled: September 28, 2020Date of Patent: February 21, 2023Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: James Bradner, Dennis Buckley, Georg Winter
-
Patent number: 11578075Abstract: The present application provides bifunctional compounds of Formula (X): or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for protein kinases. The present application also relates to methods for the targeted degradation of one or more protein kinases through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to one or more protein kinases which can be utilized in the treatment of disorders modulated by protein kinases.Type: GrantFiled: November 12, 2020Date of Patent: February 14, 2023Assignee: Dana-Farber Cancer Institute, Inc.Inventors: James Bradner, Dennis Buckley, Mette Ishoey Rosenbaum, Georg Winter
-
Publication number: 20220135967Abstract: The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.Type: ApplicationFiled: January 20, 2022Publication date: May 5, 2022Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Dennis Buckley, Georg Winter, Andrew J. Phillips, Timothy Heffernan, James Bradner, Justin Roberts, Behnam Nabet
-
Patent number: 11311609Abstract: This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.Type: GrantFiled: February 8, 2018Date of Patent: April 26, 2022Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: James Bradner, Justin Roberts, Behnam Nabet, Georg Winter, Andrew J. Phillips, Timothy P. Heffernan, Dennis Buckley
-
Patent number: 11293023Abstract: The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.Type: GrantFiled: February 6, 2018Date of Patent: April 5, 2022Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Dennis Buckley, Georg Winter, Andrew J. Phillips, Timothy Heffernan, James Bradner, Justin Roberts, Behnam Nabet
-
Publication number: 20210301286Abstract: This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.Type: ApplicationFiled: May 27, 2021Publication date: September 30, 2021Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: James Bradner, Justin Roberts, Behnam Nabet, Georg Winter, Andrew J. Phillips, Timothy Heffernan, Dennis Buckley
-
METHOD FOR IDENTIFYING A CHEMICAL COMPOUND OR AGENT INDUCING UBIQUITINATION OF A PROTEIN OF INTEREST
Publication number: 20210293788Abstract: The present invention relates to a method for identifying compounds or agents able to induce ubiquitination of a protein of interest. Further, the present invention relates to compounds/agents obtainable by the method of the present invention. Furthermore, the present invention relates to a method for treating cancer or other diseases comprising administering the chemical compound or agent obtainable by the method of the present invention. Moreover, the present invention relates to a eukaryotic cell comprising enhanced cullin-RING ubiquitin ligase (CRL) activity and/or constantly neddylated cullin-RING ubiquitin ligases/CRLs.Type: ApplicationFiled: October 16, 2019Publication date: September 23, 2021Applicant: CeMM - Forschungszentrum für Molekulare Medizin GmbHInventors: Georg WINTER, Cristina MAYOR RUIZ -
Patent number: 11059801Abstract: The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of cancer.Type: GrantFiled: April 2, 2020Date of Patent: July 13, 2021Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: James Bradner, Dennis Buckley, Georg Winter
-
Patent number: 11046954Abstract: This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.Type: GrantFiled: February 6, 2018Date of Patent: June 29, 2021Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: James Bradner, Justin Roberts, Behnam Nabet, Georg Winter, Andrew J. Phillips, Timothy Heffernan, Dennis Buckley
-
Publication number: 20210061811Abstract: The present application provides bifunctional compounds of Formula (X): or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for protein kinases. The present application also relates to methods for the targeted degradation of one or more protein kinases through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to one or more protein kinases which can be utilized in the treatment of disorders modulated by protein kinases.Type: ApplicationFiled: November 12, 2020Publication date: March 4, 2021Applicant: Dana-Farber Cancer Institute, Inc.Inventors: James BRADNER, Dennis BUCKLEY, Mette Ishoey ROSENBAUM, Georg WINTER
-
Patent number: 10925868Abstract: The present application provides bifunctional compounds of Formula (I): or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for protein kinases (e.g., Bcr-Abl). The present application also relates to methods for the targeted degradation of one or more protein kinases through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to one or more protein kinases which can be utilized in the treatment of disorders modulated by protein kinases.Type: GrantFiled: November 10, 2017Date of Patent: February 23, 2021Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Nathanael S. Gray, James Bradner, Li Tan, Hai-Tsang Huang, Dennis Buckley, Georg Winter, Mette Ishoey Rosenbaum
-
Patent number: 10899768Abstract: The present application provides bifunctional compounds of Formula (X): or an enantiomer, diastereomer, or stereoisomer thereof, or pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, which act as protein degradation inducing moieties for protein kinases. The present application also relates to methods for the targeted degradation of one or more protein kinases through the use of the bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to one or more protein kinases which can be utilized in the treatment of disorders modulated by protein kinases.Type: GrantFiled: November 22, 2017Date of Patent: January 26, 2021Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: James Bradner, Dennis Buckley, Mette Ishoey Rosenbaum, Georg Winter
-
Publication number: 20210015929Abstract: The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.Type: ApplicationFiled: September 28, 2020Publication date: January 21, 2021Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: James Bradner, Dennis Buckley, Georg Winter
-
Patent number: 10849980Abstract: The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.Type: GrantFiled: January 31, 2019Date of Patent: December 1, 2020Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: James Bradner, Dennis Buckley, Georg Winter
-
Publication number: 20200317635Abstract: The present application provides bifunctional compounds which act as protein degradation inducing moieties. The present application also relates to methods for the targeted degradation of endogenous proteins through the use of the bifunctional compounds that link a cereblon-binding moiety to a ligand that is capable of binding to the targeted protein which can be utilized in the treatment of proliferative disorders. The present application also provides methods for making compounds of the application and intermediates thereof.Type: ApplicationFiled: April 2, 2020Publication date: October 8, 2020Applicant: Dana-Farber Cancer Institute, Inc.Inventors: James Bradner, Dennis Buckley, Georg Winter